ro13-9904 and Cholera

ro13-9904 has been researched along with Cholera* in 4 studies

Reviews

1 review(s) available for ro13-9904 and Cholera

ArticleYear
Global status of antimicrobial resistance among environmental isolates of Vibrio cholerae O1/O139: a systematic review and meta-analysis.
    Antimicrobial resistance and infection control, 2022, 04-25, Volume: 11, Issue:1

    Vibrio cholerae O1/O139 were the predominant circulating serogroups exhibiting multi-drug resistance (MDR) during the cholera outbreak which led to cholera treatment failures.. This meta-analysis aimed to evaluate the weighted pooled resistance (WPR) rates in V. cholerae O1/O139 isolates obtained from environmental samples.. We systematically searched the articles in PubMed, Scopus, and Embase (until January 2020). Subgroup analyses were then employed by publication year, geographic areas, and the quality of studies. Statistical analyses were conducted using STATA software (ver. 14.0).. A total of 20 studies investigating 648 environmental V. cholerae O1/O139 isolates were analysed. The majority of the studies were originated from Asia (n = 9). In addition, a large number of studies (n = 15 i.e. 71.4%) included in the meta-analysis revealed the resistance to cotrimoxazole and ciprofloxacin. The WPR rates were as follows: cotrimoxazole 59%, erythromycin 28%, tetracycline 14%, doxycycline 5%, and ciprofloxacin 0%. There was increased resistance to nalidixic acid, cotrimoxazole, furazolidone, and tetracycline while a decreased resistance to amoxicillin, ciprofloxacin, erythromycin, chloramphenicol, ampicillin, streptomycin, and ceftriaxone was observed during the years 2000-2020. A significant decrease in the doxycycline and ciprofloxacin-resistance rates in V. cholerae O1/O139 isolates was reported over the years 2011-2020 which represents a decrease in 2001-2010 (p < 0.05).. Fluoroquinolones, gentamicin, ceftriaxone, doxycycline, kanamycin, and cefotaxime showed the highest effectiveness and the lowest resistance rate. However, the main interest is the rise of antimicrobial resistance in V. cholerae strains especially in low-income countries or endemic areas, and therefore, continuous surveillance, careful appropriate AST, and limitation on improper antibiotic usage are crucial.

    Topics: Anti-Bacterial Agents; Ceftriaxone; Cholera; Ciprofloxacin; Doxycycline; Drug Resistance, Bacterial; Erythromycin; Humans; Microbial Sensitivity Tests; Trimethoprim, Sulfamethoxazole Drug Combination; Vibrio cholerae O1; Vibrio cholerae O139

2022

Other Studies

3 other study(ies) available for ro13-9904 and Cholera

ArticleYear
Resistance to ceftriaxone in Vibrio cholerae.
    The Indian journal of medical research, 2012, Volume: 136, Issue:4

    Topics: Anti-Bacterial Agents; Ceftriaxone; Child, Preschool; Cholera; Drug Resistance, Bacterial; Female; Humans; Infant; Male; Vibrio cholerae

2012
Nonserogroup O1 Vibrio cholerae in a renal transplant patient.
    Transplantation, 2007, Mar-15, Volume: 83, Issue:5

    Topics: Adult; Anti-Bacterial Agents; Ceftriaxone; Cholera; Ciprofloxacin; Humans; Kidney Transplantation; Male; Piperacillin; Reoperation; Treatment Outcome; Vibrio cholerae O1

2007
Development of Aeromonas hydrophila bacteremia in a patient recovering from cholera.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1996, Volume: 22, Issue:5

    Topics: Adult; Aeromonas; Bacteremia; Ceftriaxone; Cephalosporins; Cholera; Cross Infection; Drug Resistance, Microbial; Female; Gram-Negative Bacterial Infections; Humans

1996